- Home
- MCN vs ALDX Comparison
MCN vs ALDX Comparison
Compare MCN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCN | ALDX |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.0M | 103.1M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MCN | ALDX |
|---|---|---|
| Price | $5.49 | $1.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 89.4K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.46 | $1.07 |
| 52 Week High | $6.39 | $6.18 |
Technical Indicators
Market Signals| Indicator | MCN | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 22.84 | 49.01 |
| Support Level | N/A | $1.49 |
| Resistance Level | $6.02 | $1.91 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 5.89 | 24.11 |
Price Performance
Historical ComparisonAbout MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.